Inactive Instrument

Other languages Entasis Therapeutics Holdings Inc.

Equities

ETTX

US2936141033

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Entasis Therapeutics Holdings Inc. Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial At IDWEEK 2022	22-10-19
Innoviva, Inc. completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. from a group of shareholders.	22-07-10
Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash; Entasis Stock Surges Pre-Bell	22-05-23
Entasis Therapeutics Holdings Inc. Presents Data Highlights from Phase 3 Attack Trial At 2022 American Thoracic Society Annual Conference	22-05-17
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference	22-04-26
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-03
Entasis Therapeutics Holdings Inc. Auditor Raises 'Going Concern' Doubt	22-03-02
Entasis Therapeutics Holdings Inc. Announces Executive Changes	22-02-25
Entasis Therapeutics Receives Cash Buyout Proposal From Innoviva at $1.80/Share; Shares Slide After-Hours	22-02-02
Entasis Therapeutics Holdings Inc. Announces Resignation of Michael Gutch as Chief Business Officer, Effective February 24, 2022	22-01-14
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-04
Zai Lab : Entasis Say Sulbactam-Durlobactam Met Primary Endpoint in Phase 3 Trial in Acinetobacter Infection	21-10-19
Entasis Therapeutics : Says Phase 3 Trial of Antibiotic for Drug-Resistant Infection Shows Better Mortality Rate Versus Colistin; Shares Jump in Pre-Market	21-10-19
Entasis Therapeutics : Says Phase 3 Trial of Antibiotic for Drug-Resistant Infection Shows Better Mortality Rate Versus Colistin; Shares Jump After Hours	21-10-18
Entasis Therapeutics : Phase 3 Trial of Antibiotic for Drug-Resistant Infection Shows Better Mortality Rate Versus Colistin	21-10-18
Entasis Therapeutics : Says New Antibiotic for Drug-Resistant Infections Profiled in Nature, Shares Up	21-09-16
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-11
Entasis Therapeutics : , Zai Lab Complete Enrollment in Phase 3 Trial of Drug Candidate for Acinetobacter Infections	21-07-27
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Entasis Therapeutics Holdings Inc.

Equities

ETTX

US2936141033

Other languages

Filters